Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre phase II trial to determine the efficacy of RAD 001 (everolimus, Afinitor) as second line therapy in patients with transitional cell carcinoma (TCC) of the urothelium which failed or progressed after first line chemotherapy.

Next Previous
Trial Profile

A multicentre phase II trial to determine the efficacy of RAD 001 (everolimus, Afinitor) as second line therapy in patients with transitional cell carcinoma (TCC) of the urothelium which failed or progressed after first line chemotherapy.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 May 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary)
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms AFINIVEST

Most Recent Events

  • 02 Jun 2015 Primary endpoint (Progression-free survival rate) has been met, according to abstract presented at ASCO 2015.
  • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO 2015).
  • 02 Jun 2015 Status changed from recruiting to completed, as reported in ASCO 2015 abstract.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top